BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Sanofi  Pasteur  MSD  submitted  on    04  June  2004  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  M-M-RVAXPRO,  through  the 
centralised  procedure  falling  within  the  Article  3(1)  and  point  1  of  Annex  of  Regulation  (EC) 
No 726/2004.  
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
The application submitted is a complete dossier: 
composed of administrative information, complete quality data, non-clinical and clinical data based on 
applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain test(s) 
or study(ies). 
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur:  M Haase 
Co-Rapporteur:       P Neels 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 16 November 2000. The Scientific 
Advice pertained to quality, non-clinical and clinical aspects of the dossier.  
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 4 June 2004.  
The procedure started on 19 July 2004. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on 
29 September 2004. The Co-Rapporteur's first Assessment Report was circulated to all CHMP 
members on 4 October 2004.  
The BWP during its meeting of 8-10 November 2004 adopted the BWP Report to be transmitted 
to the CHMP for endorsement. 
During  the  meeting  on  15-18  November  2004,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on  19 November 2004. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
24 November 2005. 
The  summary  report  of  the  inspection  carried  out  at  the  following  site  Merck  &  Co.,  Inc., 
Sumneytown Pike, West Point, Pennsylvania, USA between 8 – 10 February 2006 was issued 
on 2 May 2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 5 January 2006. 
The BWP during its meeting of 17-18 January 2006 adopted the BWP Report to be transmitted 
to the CHMP for endorsement. 
During the CHMP meeting on 23-26 January 2006, the CHMP agreed on a list of outstanding 
issues to be addressed in writing by the applicant. 
1/2 
©EMEA 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
• 
The  applicant  submitted  the  responses  to  the  CHMP  list  of  outstanding  issues  on 
3 February 2006. 
During  the  meeting  on  21-23  February  2006,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting  a  Marketing  Authorisation  to  M-M-RVAXPRO  on  23  February  2006.  The  applicant 
provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation 
on 23 February 2006 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 5 May 2006. 
2/2 
©EMEA 2006 
 
